Kyorin Pharmaceutical Co (TSE:4569) 3-Year EBITDA Growth Rate : -2.20% (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Kyorin Pharmaceutical Co 3-Year EBITDA Growth Rate?

Kyorin Pharmaceutical Co's EBITDA per Share for the three months ended in Dec. 2023 was 円49.04.

During the past 12 months, Kyorin Pharmaceutical Co's average EBITDA Per Share Growth Rate was -20.60% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -2.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -0.20% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -5.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Kyorin Pharmaceutical Co was 25.50% per year. The lowest was -14.80% per year. And the median was 3.15% per year.

Competitive Comparison of Kyorin Pharmaceutical Co's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kyorin Pharmaceutical Co's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Kyorin Pharmaceutical Co's 3-Year EBITDA Growth Rate falls into.

Kyorin Pharmaceutical Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Kyorin Pharmaceutical Co (TSE:4569) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Kyorin Pharmaceutical Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Kyorin Pharmaceutical Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyorin Pharmaceutical Co (TSE:4569) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyorin Pharmaceutical Co Ltd (TSE:4569) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311

Website

https://www.kyorin-pharm.co.jp

Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.

Kyorin Pharmaceutical Co (TSE:4569) Headlines

No Headlines